Cargando…

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

A large body of clinical and nonclinical evidence supports the role of neurotoxic soluble beta amyloid (amyloid, Aβ) oligomers as upstream pathogenic drivers of Alzheimer’s disease (AD). Recent late-stage trials in AD that have evaluated agents targeting distinct species of Aβ provide compelling evi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tolar, Martin, Hey, John, Power, Aidan, Abushakra, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231952/ https://www.ncbi.nlm.nih.gov/pubmed/34198582 http://dx.doi.org/10.3390/ijms22126355

Ejemplares similares

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
por: Hey, John A., et al.
Publicado: (2018)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
por: Hey, John A., et al.
Publicado: (2017)

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
por: Abushakra, Susan, et al.
Publicado: (2020)

Quantification and targeting of elusive neurotoxic amyloid oligomers
por: Bhatt, Nemil, et al.
Publicado: (2022)

Amyloid Oligomer Neurotoxicity, Calcium Dysregulation, and Lipid Rafts
por: Malchiodi-Albedi, Fiorella, et al.
Publicado: (2011)

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?
por: Broersen, Kerensa, et al.
Publicado: (2010)

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
por: Ferreira, Sergio T., et al.
Publicado: (2015)

Hyperactivity Induced by Soluble Amyloid-β Oligomers in the Early Stages of Alzheimer's Disease
por: Hector, Audrey, et al.
Publicado: (2021)

A dopamine metabolite stabilizes neurotoxic amyloid-β oligomers
por: Cataldi, Rodrigo, et al.
Publicado: (2021)

An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
por: Sciaccaluga, Miriam, et al.
Publicado: (2021)

Nanoscopic insights into the surface conformation of neurotoxic amyloid β oligomers
por: Banchelli, Martina, et al.
Publicado: (2020)

Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils
por: Ahmed, Mahiuddin, et al.
Publicado: (2010)

Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin
por: Shin, Thuzar M, et al.
Publicado: (2008)

Tau Oligomers Neurotoxicity
por: Niewiadomska, Grazyna, et al.
Publicado: (2021)

Disruption of Amyloid Plaques Integrity Affects the Soluble Oligomers Content from Alzheimer Disease Brains
por: Jimenez, Sebastian, et al.
Publicado: (2014)

Hippocampal injections of soluble amyloid-beta oligomers alter electroencephalographic activity during wake and slow-wave sleep in rats
por: Hector, Audrey, et al.
Publicado: (2023)

The neurotoxicity of amyloid β-protein oligomers is reversible in a primary neuron model
por: Tanokashira, Daisuke, et al.
Publicado: (2017)

Publisher Correction: A dopamine metabolite stabilizes neurotoxic amyloid-β oligomers
por: Cataldi, Rodrigo, et al.
Publicado: (2021)

Protection against Amyloid-β Oligomer Neurotoxicity by Small Molecules with Antioxidative Properties: Potential for the Prevention of Alzheimer’s Disease Dementia
por: Araki, Wataru, et al.
Publicado: (2022)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Synthetic amyloid-β oligomers drive early pathological progression of Alzheimer’s disease in nonhuman primates
por: Yue, Feng, et al.
Publicado: (2021)

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
por: Haass, Christian, et al.
Publicado: (2022)

Soluble Amyloid Oligomers Increase Bilayer Conductance by Altering Dielectric Structure
por: Sokolov, Yuri, et al.
Publicado: (2006)

Probing the Occurrence of Soluble Oligomers through Amyloid Aggregation Scaling Laws
por: Silva, Alexandra, et al.
Publicado: (2018)

An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect
por: Liu, Yu-Hui, et al.
Publicado: (2015)

An N-terminal Fragment of the Prion Protein Binds to Amyloid-β Oligomers and Inhibits Their Neurotoxicity in Vivo
por: Fluharty, Brian R., et al.
Publicado: (2013)

Role of Electrostatic Interactions in Calcitonin Prefibrillar Oligomer-Induced Amyloid Neurotoxicity and Protective Effect of Neuraminidase
por: Cariati, Ida, et al.
Publicado: (2021)

Brain Hydrophobic Peptides Antagonists of Neurotoxic Amyloid β Peptide Monomers/Oligomers–Protein Interactions
por: Gutierrez-Merino, Carlos
Publicado: (2023)

Reversibility of Aβ oligomer neurotoxicity
por: Araki, Wataru
Publicado: (2017)

Altered synaptic structure in the hippocampus in a mouse model of Alzheimer’s disease with soluble amyloid-β oligomers and no plaque pathology
por: Price, Katherine A, et al.
Publicado: (2014)

AmyP53 Prevents the Formation of Neurotoxic β-Amyloid Oligomers through an Unprecedent Mechanism of Interaction with Gangliosides: Insights for Alzheimer’s Disease Therapy
por: Azzaz, Fodil, et al.
Publicado: (2023)

Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer’s and Parkinson’s Disease
por: Gutierrez, Berenice A., et al.
Publicado: (2022)

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
por: Balducci, Claudia, et al.
Publicado: (2019)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers
por: Bitencourt, André L. B., et al.
Publicado: (2020)

Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease
por: Serra-Batiste, Montserrat, et al.
Publicado: (2018)

In Vitro and In Vivo Neurotoxicity of Prion Protein Oligomers
por: Simoneau, Steve, et al.
Publicado: (2007)

Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology
por: Salminen, Antero, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_ja7fag8ahrjftorllnrvh8c3ig